Recently, Beilu Pharmaceutical received the Drug Registration Certificate for Ioflufenicol Injection issued by the National Medical Products Administration .
The original manufacturer of Ioflucanol injection is Mallinckrodt in the United States. Its indications are: (1) coronary angiography and left ventricle angiography, aortic angiography, peripheral and visceral artery angiography in adults; (2) enhanced CT scan of the head and body in adults, venography and excretory urography; (3) cardiovascular angiography in children.
Ioflufenicol injection has been included in the National Medical Insurance Category A Catalog. According to data from Menet.com, the sales of Ioflufenicol injection in China's three major terminals and six major markets have been increasing year by year in recent years, exceeding 3 billion yuan in each of the three major terminals and six major markets from 2023 to 2025. It has consistently ranked first among contrast agents (chemical drugs + biological drugs).
Ioflufenicol injection has been approved as a Class 4 chemical drug, which is considered equivalent to passing the consistency evaluation of generic drug quality and efficacy, further enriching the company's portfolio of iodine-based contrast agents. In addition to ioflufenicol injection, the company's iodine-based contrast agent products also include iohexol injection, iodixanol injection, iopamidol injection, iomeptin injection, and iopromide injection , making the company's contrast agent product line more diversified and enhancing its market competitiveness. The company will actively carry out various preparations for the launch of new products and bring them to market as soon as possible.

https://bydrug.pharmcube.com/news/detail/5c5dccc84614c92d80814067fe74516f